Ab Initio Pharma
- Company typePrivate
- Founded2019
- HeadquartersCamperdown, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
Ab Initio Pharma firmographics
Firmographics- Name
- Ab Initio Pharma
- Legal name
- Abinitio
- Website
- https://ab-initio-pharma.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ab Initio Pharma industry classification
Industry- Product category
- Contract Pharmaceutical Development and Manufacturing (CDMO/CRO Services)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)
Keywords
Where Ab Initio Pharma is headquartered
LocationHeadquarters
- HQ city
- Camperdown
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Ab Initio Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services - R&D and Formulation: Project-based fees for research and development services including formulation development, preclinical formulation studies, and stability testing for drug candidates progressing toward clinical stages.
- GMP Manufacturing Services: Fees for GMP manufacturing of clinical trial material including production, fill-finish, quality release, and stability programs for Phase 1, 2, and 3 trials.
- CRO Clinical Trial Services: Comprehensive clinical research services including trial coordination, regulatory and ethics submissions, clinical supply oversight, site management, and data management.
- Technology Transfer Services: Fees for tech transfer programs including pMDI (pressurized Metered Dose Inhaler) transfers, formulation optimization, and ICH stability programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based custom pricing - quotes provided per engagement |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Ab Initio Pharma product offering
Product offeringCore offering
Ab Initio Pharma is an integrated pharmaceutical CDMO and CRO providing three core services under its 'Power of Three' model: (1) R&D formulation innovation for complex dosage forms (inhaled, intranasal, topical gel, oral, oligonucleotide), (2) GMP-compliant manufacturing of clinical trial materials including fill-finish, packaging, labeling, and release, and (3) clinical trial support spanning trial coordination, regulatory and ethics submissions, clinical supply oversight, and site/data management for Phase 1–3 studies. The company delivers end-to-end drug development services to biotech startups, listed pharmaceutical firms, and research institutions.
Product overview
Ab Initio Pharma operates as an integrated pharmaceutical Contract Development and Manufacturing Organisation (CDMO) and Contract Research Organisation (CRO), offering three core services under the 'Power of Three' model: R&D (Research & Development) for formulation innovation, GMP Manufacturing for quality production at scale, and Clinical Trial Support for complete trial execution. The company serves biotech startups and pharmaceutical clients worldwide, providing end-to-end solutions from bench to clinic with a reported 50+ successfully developed products, 98% completion rate, and ability to progress products from development to clinical trial in 18 months.
Differentiator
Problem solved
Functional benefit
Products and services
- R&D (Research & Development) Formulation Innovation Innovation and formulation development services that transform scientific ideas into stable, effective drug formulations for complex dosage forms, targeted at biotech startups, pharmaceutical companies, and research institutions.
- GMP Manufacturing Quality-focused pharmaceutical manufacturing services ensuring consistency, scalability, and compliance with Good Manufacturing Practice standards for clinical trial materials, including production, fill-finish, packaging, labeling, and release.
- Clinical Trial Support Full CRO services covering trial coordination, regulatory and ethics submissions, clinical supply oversight, site and data management, and packaging and labeling for Phase 1–3 clinical trials.
Quantifiable outcome
- 18 months from development initiation to first clinical trial dosing
- +4 more outcomes
Companies that use Ab Initio Pharma
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
Ab Initio Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ab Initio Pharma partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights4 records
Ab Initio Pharma competitors and assessment
Company assessmentBroad incumbents
- WuXi STA (WuXi AppTec): Large Asian CDMO with end-to-end small molecule development and manufacturing services from API to drug product. Dominant scale CDMO offering integrated services competing for global innovator work but with much broader portfolio.
- Patheon (Thermo Fisher Scientific): Global CDMO division of Thermo Fisher providing drug substance, drug product development, and clinical supply services. Broad incumbent offering the same full-spectrum CDMO capabilities Ab Initio provides but at vastly larger scale.
- Catalent: Global diversified CDMO with large-scale softgel, oral, inhalation, and biologics capabilities serving innovator pharma. Much larger incumbent competing for the same complex dosage form programs Ab Initio targets, but offering a far wider portfolio rather than integrated clinical services.
- Lonza: World's largest CDMO with capabilities spanning small molecule API, biologics, and drug product manufacturing. Provides broad industry context for valuation but is a giant incumbent spanning many modalities beyond Ab Initio's specialty complex dosage focus.
Direct peers
- PCI Pharma Services: Integrated CDMO providing drug development, manufacturing, and clinical trial supply services including packaging and labelling. Direct competitor in the integrated CDMO+CRO-adjacent model serving innovator pharma clients globally.
- Recipharm: European CDMO offering formulation development, GMP manufacturing, and clinical supply for pharma customers. Closely comparable mid-sized CDMO with broad service portfolio including fill-finish and clinical packaging similar to Ab Initio's offerings.
- Hovione: Portugal-based CDMO with deep expertise in inhaled and complex drug development including particle engineering and DPI/pMDI technology. Most directly comparable peer given shared focus on inhalation, particle engineering, and integrated formulation-to-GMP services for innovator clients.
- Kindeva Drug Delivery: CDMO specializing in inhalation, transdermal, and complex drug delivery with formulation development and clinical/commercial manufacturing. Highly relevant peer given shared focus on inhaled drug delivery, particle engineering, and GMP manufacturing for complex dosage forms.
Regional players
- Mayne Pharma Group: Australian specialty pharmaceutical company with CDMO services including topical, oral, and injectable contract manufacturing. Regional peer sharing Australian base and specializing in complex drug delivery services for global clients.
- IDT Australia: Australian contract manufacturer providing aseptic manufacturing, clinical trial supplies, and drug development services for local and international pharma. Regional peer operating in the same Australian market with overlapping CDMO capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Ab Initio Pharma social profiles
Digital presenceAb Initio Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ab Initio Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Ab Initio Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ab Initio Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ab Initio Pharma
What does Ab Initio Pharma do?
Ab Initio Pharma is an integrated pharmaceutical CDMO and CRO providing three core services under its 'Power of Three' model: (1) R&D formulation innovation for complex dosage forms (inhaled, intranasal, topical gel, oral, oligonucleotide), (2) GMP-compliant manufacturing of clinical trial materials including fill-finish, packaging, labeling, and release, and (3) clinical trial support spanning trial coordination, regulatory and ethics submissions, clinical supply oversight, and site/data management for Phase 1–3 studies. The company delivers end-to-end drug development services to biotech startups, listed pharmaceutical firms, and research institutions.
Is Ab Initio Pharma a public or private company?
Ab Initio Pharma is a private company. It is classified as unknown and is currently operating.
When was Ab Initio Pharma founded?
Ab Initio Pharma was founded in 2019. It employs 11 to 50 people.
Where is Ab Initio Pharma based?
Ab Initio Pharma is headquartered in Camperdown, Australia, in the Oceania region.
How does Ab Initio Pharma make money?
Four revenue lines are on record. CDMO Services - R&D and Formulation is the primary driver. The others are GMP Manufacturing Services, CRO Clinical Trial Services and technology Transfer Services.
Who are Ab Initio Pharma's main competitors?
Broad incumbents on record are WuXi STA (WuXi AppTec), Patheon (Thermo Fisher Scientific), Catalent and Lonza. Direct peers are PCI Pharma Services, Recipharm, Hovione and Kindeva Drug Delivery. Regional players are Mayne Pharma Group and IDT Australia.
Does Ab Initio Pharma have an API?
No public API is recorded for Ab Initio Pharma.
What industry is Ab Initio Pharma in?
Ab Initio Pharma's product category is Contract Pharmaceutical Development and Manufacturing (CDMO/CRO Services). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.